Considerations about immunotherapeutic medicines in oncology

Alain Rinaldi MD, Bratislava June 1st, 2023





MEDExpansion

Medical Intelligence at the core of innovation



Alain Rinaldi

- Clinician (F, 84 91)
 - Pediatrician, medical oncologist with hospital practice
- Pharma (F, EU, 91 2014)
 - Medical, medical affairs
 - Sanofi-Aventis, Servier, AstraZeneca
 - Alexion (2006 14)
 - Medical director France, then CH, Central & Eastern Europe countries
 - Launches of eculizumab (Soliris[®]) in FR, CH, IT, SK, CZ, PL, RO, HU, LT
- Medexpansion (CH, 2014 today)
 - Collaborations with startups in oncology in the CMO role to help transition preclinical-to-clinical
- Member of CEEHPN since 2014





Importance of facilitating access to IT drugs for better patient benefits

	1992 - 95
Metastatic melanoma 5-year survival	14%
Metastatic lung cancer Death rate	60%






2023

40%

32%


Anti-cancer therapies: the historical situation before new therapies







Genomics/NGS*, launching pad for personalized medicine 2008 - 2023






Biomarkers, specific to the patient's tumour, predictive of treatment efficacy

*Next generation sequencing of the DNA

Genomics, targeted therapies, immunotherapies and personalized medicine






Biomarkers, specific to the patient's tumour, predictive of treatment efficacy

Targeted therapies and mAbs


Genomics, targeted therapies, immunotherapies and personalized medicine





Biomarkers, specific to the patient's tumour





Immune system / T lymphocytes

Stimulate

Immunotherapies (CPIs)*

*Checkpoint inhibitors

New therapies have offered tremendous progress

• Gain of efficacy

- Prolonged survival
- Longer duration of response to treatment
- In many cases, treatment cures patients with cancer or cancer becomes a chronic disease (prostate, breast ...)

Gain of safety

• Better tolerance (less hair loss, less vomiting ...)

Greater acceptability

Frequent oral administration (targeted therapies)







Limitations to access : high costs and affordability issues (order of magnitude)

 Almost all new therapies, targeted/immunotherapies, are expensive ○ Eculizumab (orphan diseases): 470'000 € / year ○ Imatinib (lymphomas): 28'000 € / year Sofosbuvir (hepatitis C): \$ 25'000 / one time 3 months \circ CAR T cell therapies (gene therapies, leukemias ...): M\$ 0,5 – 1 / one inj. ○ Pembrolizumab (CPI, oncology): 90'000 € / year (Keytruda[®] 2022 sales \$ 20.94 billions)

→ Escalation of healthcare budgets

- Increasing numbers of approved diseases and of eligible patients Ο
 - ... and the 2023 winners are ...





• Zynteglo[®], Hemgenix[®] (gene therapies, resp. thalassemia, hemophilia B): resp. M\$ 2,8 and 3,5 / one inj.

... but precision medicine has imprecisions

• Targeted therapies

- Transient efficacy due to development of cancer resistances (mutations)
 - More expensive new generations of drugs to overcome resistances
 - G1 anti-EGFR gefitinib 9'500 €, G3 osimertinib 72'000 € (France)
 - → Strategies for escalation?
- Immunotherapies (Keytruda[®]...)
 - Only 25 45% of eligible patients (predictive biomarker PD-L1) respond to treatment
 - Costly ineffective treatments sources of toxicities
 - Image: G-month treatment with pembrolizumab 45'000 €
 - → Better patient selection?





- Expert committees to revisit criteria for optimal patient profiles • CPIs: improving predictive biomarkers
 - Targeted therapies: evidence-based recommendations for G1-Gx escalation
 - Restricting prescription to patients with best predictive benefits





- Expert committees to revisit criteria for optimal patient profiles • CPIs: improving predictive biomarkers
 - Targeted therapies: evidence-based recommendations for G1-Gx escalation
 - Restricting prescription to patients with best predictive benefits

Negotiating with pharmaceutical companies

- Price negotiation Ο
- Limiting budget envelope with payback Ο
- Cost-sharing mechanisms Ο





- Expert committees to revisit criteria for optimal patient profiles • CPIs: improving predictive biomarkers
 - Targeted therapies: evidence-based recommendations for G1-Gx escalation
 - Restricting prescription to patients with best predictive benefits
- **Negotiating with pharmaceutical companies**
 - Price negotiation
 - Limiting budget envelope with payback
 - **Cost-sharing mechanisms**
- Monitoring prescription
 - Framing prescription: reference centres/experts/centre networks with exclusive habilitation (France: reference centre/competency centres for orphan diseases)
 - Evaluation of individual results of patient treatment for drug renewal



MEDExpansion

- Expert committees to revisit criteria for optimal patient profiles • CPIs: improving predictive biomarkers
 - Targeted therapies: evidence-based recommendations for G1-Gx escalation
 - Restricting prescription to patients with best predictive benefits
- Negotiating with pharmaceutical companies
 - Price negotiation
 - Limiting budget envelope with payback
 - **Cost-sharing mechanisms**
- **Monitoring prescription**
 - Framing prescription: reference centres/experts/centre networks with exclusive habilitation (France: reference centre/competency centres for orphan diseases)
 - Evaluation of individual results of patient treatment for drug renewal

Reassessing clinical value

- Expert committee that assesses the robustness of the submission dossier and rates the clinical value for registration on a specialty list
- Patient registry with regular global analyses Ο





- Expert committees to revisit criteria for optimal patient profiles • CPIs: improving predictive biomarkers
 - Targeted therapies: evidence-based recommendations for G1-Gx escalation
 - Restricting prescription to patients with best predictive benefits

Negotiating with pharmaceutical companies

- Price negotiation
- Limiting budget envelope with payback
- Cost-sharing mechanisms Ο

Monitoring prescription •

- Framing prescription: reference centres/experts/centre networks with exclusive habilitation (France: reference centre/competency centres for orphan diseases)
- Evaluation of individual results of patient treatment for drug renewal

Reassessing clinical value \bullet

- Expert committee that assesses the robustness of the submission dossier and rates the clinical value for registration on a specialty list
- Patient registry with regular global analyses Ο



Thank you !

<u>a.rinaldi@medexpansion.ch</u> <u>https://www.linkedin.com/in/alainrinaldi/</u>







MEDExpansion

Medical Intelligence at the core of innovation